Allergan (NYSE: AGN) chief executive Brent Saunders faces a second headache in as many days, after activist investor Appaloosa stepped up the pressure for an independent chairman at the company.
On Wednesday the firm revealed its innovative depression therapy rapastinel flopped three pivotal studies, striking a blow to hopes that Allergan could rival Johnson & Johnson’s (NYSE: JNJ) newly-approved option Spravato (esketamine).
Analysts have also expressed concern over the thinness of the company's late-stage pipeline.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze